Here's my guess. INO trades much more on sentiment -as opposed to- traditional financial performance metrics over time. This is a given; she goes up on positive news and is faded on highs, by the 'time to fade the overly positive sentiment' crowd.
Sentiment appears to be fading since Roche. So she is likely to be weighed down until sentiment improves especially if the general stock market goes sour. Catalyst are (1) increase institutional ownership, (2) P-ship news, (3) Ebola funding news, (4) Study trial news.
So, it appears the company must step up to the plate to counter the Roche story's impact on sentiment ---> if they are concerned about the stock price. Which is the funny thing here... because imho INO has the science part right, which in the end is all that really matters. For Longs, for example, I'm not happy with the price but also not worried. Unique as a holding, and not trading... we'll see how this perspective does, there is some comfort in not having to trade her. IMHO the real risk is to being out when things will break for the longs. The flip side is just about every trading book I've read says that's a trade mistake. But, in the market No rule is 100%; just ask those Investors who held APPL and MCD through thick and thin. GLTAL's.
News 
Market Data 
Discover 
